Smart Nanoformulations for Brain Cancer Theranostics: Challenges and Promises
Despite their low prevalence, brain tumors are among the most lethal cancers. They are extremely difficult to diagnose, monitor and treat. Conventional anti-cancer strategies such as radio- and chemotherapy have largely failed, and to date, the development of even a single effective therapeutic stra...
Main Authors: | Faraz Ahmad, Ressin Varghese, Subhrajita Panda, Siva Ramamoorthy, Mohammad Y. Areeshi, Sharmila Fagoonee, Shafiul Haque |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/21/5389 |
Similar Items
-
Aptamer-based Theranostics in Oncology: Design Strategies and Limitations
by: Jyoti Trivedi, et al.
Published: (2024-04-01) -
Exosomes and Extracellular Vesicles as Emerging Theranostic Platforms in Cancer Research
by: Giorgia Ailuno, et al.
Published: (2020-12-01) -
Exosomes and ultrasound: The future of theranostic applications
by: Badrinathan Sridharan, et al.
Published: (2023-04-01) -
Recent Advancements, Challenges, and Future Prospects in Usage of Nanoformulation as Theranostics in Inflammatory Diseases
by: Amit K. Goyal, et al.
Published: (2023-03-01) -
Design Principles Governing the Development of Theranostic Anticancer Agents and Their Nanoformulations with Photoacoustic Properties
by: Stavroula G. Kyrkou, et al.
Published: (2022-02-01)